A 41-year old male with insulin-dependent diabetes mellitus previously unsuccessfully treated with a controlled diet and glibenclamide, and subsequently with increasing insulin doses (5 and 20 IU/day) experienced polyuria, glycosuria and loss of weight. On admittance to hospital serum C3 concentrations were found to be depressed. The insulin dose was further increased to 30 IU/day and the patient was also treated with 20 mg nafamostat mesylate given intravenously twice daily for 6 days. On completion of nafamostat mesylate treatment serum C3 concentrations were increased but after 17 days they started to decrease again.
DobersenMJScharffJEGinsberg-FellnerFCytotoxic autoantibodies to beta cells in the serum of patients with insulin-dependent diabetes mellitus. N Engl J Med1980; 303: 1493–1498.
2.
OkadaSSatoKMiyaiYSerum C3 and C4 levels and complement-dependent antibody-mediated cytotoxic activity of islet cell surface antibody in type 1 (insulin-dependent) diabetic children. Diabetologia1987; 30: 869–873.
3.
OkadaSIchikiKSatoKComplement activation pathway associated with islet cell surface antibody (ICSA) derived from child patients with insulin-dependent diabetes mellitus (IDDM). Acta Med Okayama1991; 45: 185–186.
4.
OkadaSSatoKIchikiKDoes protease inhibitor inhibit complement activation caused by immune complex in association with islet cell surface antibody?J Int Med Res1991; 19: 234–236.
5.
AoyamaTInoYOzekiMPharmacological studies of FUT-175, nafamostat mesylate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol1984; 35: 203–227.
6.
LemmarkASehlinJTaljedalT-BPossible toxic effects of normal and diabetic patient serum of pancreatic B cells. Diabetologia1978; 14: 25–31.
